Overview

A Long Term Safety Study of BCX7353 in Hereditary Angioedema

Status:
Active, not recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label study to evaluate the long term safety and effectiveness of oral treatment with BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
BioCryst Pharmaceuticals
Treatments:
Berotralstat